X-linked hypophosphatemia is a rare inherited disorder that prevents the body from properly processing phosphate and is estimated to affect 1 in 20,000 individuals. This genetic bone disease is characterized by low phosphate levels in the blood, with bone pain, dental problems, and hearing loss as the common symptoms. The rising advancements in genetic and molecular research including a better understanding of the genetic mutations that cause X-linked hypophosphatemia are likely to stimulate the development of targeted therapies in the coming years.
Major companies involved in the X-linked hypophosphatemia (XLH) pipeline drugs market include Kyowa Kirin, Inc. and Ultragenyx Pharmaceutical Inc., among others.
Leading drugs currently under the pipeline include INZ-701 and KK8123, among others.
The growing focus on the development of novel therapeutic agents such as monoclonal antibodies is anticipated to positively influence the drug pipeline landscape.
The X-linked Hypophosphatemia (XLH) Drug Pipeline Insight Report by Expert Market Research gives comprehensive insights into X-linked hypophosphatemia (XLH) drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for X-linked hypophosphatemia (XLH). The report includes the analysis of over 100 pipeline drugs and 50+ companies. The X-linked hypophosphatemia (XLH) pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from X-linked hypophosphatemia (XLH).
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to X-linked hypophosphatemia (XLH).
X-linked hypophosphatemia (XLH) is considered the most common cause of inherited phosphate wasting. It is linked with serious complications including disproportionate short stature in children, rickets, hyperparathyroidism, poor mineralization of the teeth, and lower limb deformities. The characteristics and severity of this inherited disorder show significant variability between patients.
Phosphate supplements and vitamin D (calcitriol) can help in addressing the metabolic causes of the disease, reducing or even reversing the symptoms in children. Bursomab, an FDA-approved monoclonal antibody treatment for X-linked hypophosphatemia is also used for increasing the phosphate levels in the blood. With the growing focus on developing medications that target specific pathways involved in X-linked hypophosphatemia, the drug pipeline is anticipated to witness a steady expansion in the near future.
This section of the report covers the analysis of X-linked hypophosphatemia (XLH) drugs based on several segmentations including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I and II cover a major share of the total clinical trials for X-linked hypophosphatemia (XLH).
The drug molecule categories covered under the X-linked hypophosphatemia (XLH) pipeline analysis include monoclonal antibodies, enzyme replacement therapies, gene therapies, and small molecules. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for X-linked hypophosphatemia (XLH).
The EMR report for the X-linked hypophosphatemia (XLH) drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in X-linked hypophosphatemia (XLH) clinical trials:
Major drugs currently in the drug pipeline are as follows:
Sponsored by Inozyme Pharma, the objective of this open-label Phase II interventional study is to investigate the long-term safety of investigational drug candidate INZ-701 in an estimated 200 subjects with ENPP1 deficiency or ABCC6 deficiency. The study is expected to be completed by December 2030 and has the potential to treat autosomal recessive hypophosphatemic rickets type 2, a form of X-linked hypophosphatemia.
This Phase 1/2 dose-escalation study (with an optional safety extension period) is aimed at evaluating the safety, tolerability, and efficacy of KK8123 in adults with X-linked hypophosphatemia. The interventional study has enrolled an estimated 24 subjects and is expected to be completed by October 2028.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The X-linked hypophosphatemia (XLH) Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for X-linked hypophosphatemia (XLH). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within X-linked hypophosphatemia (XLH) pipeline insights.
X-Linked Adrenoleukodystrophy (X-ALD) Drug Pipeline Insight Report
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share